Halcygen Pharmaceuticals Limited (HGN) operates as a
licensee and developer of pharmaceutical formulations.
HalcyGen, through its license agreements with Mayne Pharma
International, develops and registers pharmaceutical
formulations known as SuperGenerics: SUBA-Itraconazole and Minocycline.